Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F, Tsekoura C, Voscaridou E, Boussiotis V, Rombos J, Vayopoulos G
University of Athens Medical School, Laikon General Hospital, Greece.
Eur J Cancer. 1991;27 Suppl 4:S69-71. doi: 10.1016/0277-5379(91)90578-2.
The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 x 10(9)/L was achieved in 94%, and below 400 x 10(9)/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.
对18例骨髓增殖性疾病合并血小板增多症（9例原发性血小板增多症、3例真性红细胞增多症、3例骨髓纤维化和3例慢性粒细胞白血病）患者，研究了重组干扰素α-2b对血小板计数、血小板增多相关症状及骨髓纤维化的影响。治疗8至330天内，94%的患者血小板计数降至600×10⁹/L以下，77%的患者降至400×10⁹/L以下。多数患者α干扰素的选择性降低血小板作用长期维持，且无严重副作用。血小板数降至接近正常水平后，血小板增多相关症状缓解。在研究的7例患者中，有2例治疗后骨髓网硬蛋白含量降低。α干扰素的副作用为流感样症状，通常在治疗7天内消退。
